MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ene.16450

Медицинская библиотека · European journal of neurology · 2024

Association of anti-calcitonin gene-related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study.

Iannone Luigi Francesco, Romozzi Marina, Russo Antonio, Saporito Gennaro, De Santis Federico, Ornello Raffaele, Sances Grazia, Vaghi Gloria, Tassorelli Cristina, Albanese Maria, Guerzoni Simona, Casalena Alfonsina, Vollono Catello, Calabresi Paolo, Prudenzano Maria Pia, Mampreso Edoardo, Volta Giorgio Dalla, Valente Maria Rosaria, Avino Gianluca, Chiarugi Alberto, Sacco Simona, Pistoia Francesca, Italian Headache Registry (RICe) study group

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND AND PURPOSE: Although there is extensive evidence about the safety of monoclonal antibodies against calcitonin gene-related peptide (anti-CGRP mAbs) in combination with traditional drugs, scarce data are available on the safety of their combination with other mAbs. This study aimed to evaluate the 6-month effectiveness and tolerability of anti-CGRP mAbs in combination with other mAbs for different diseases.

METHODS

Patients included in the Italian Headache Registry and treated concomitantly with an anti-CGRP mAb and another mAb were included. Effectiveness outcomes for migraine included reduction from baseline of monthly headache days (MHDs), Migraine Disability Assessment (MIDAS) score, Headache Impact Test-6 (HIT-6) scores, and Patients' Global Impression of Change (PGIC) scale. Adverse events (AEs) were recorded.

RESULTS

Thirty-eight patients were included. In 27 patients (71.1%), the anti-CGRP mAb was added to a previously ongoing mAb. Nine patients (23.7%) discontinued one of the two mAbs before the end of treatment (seven discontinued the anti-CGRP mAb and two the other mAb). One patient discontinued for AEs. Anti-CGRP mAbs were discontinued due to ineffectiveness (n = 5, 55.5%) and one each (11.1%) for clinical remission and lost to follow-up. MHDs significantly decreased from baseline to 3 months (p < 0.0001) and 6 months (p < 0.001), as did the MIDAS and the HIT-6 scores at 3 and 6 months (p < 0.001). For anti-CGRP mAbs, 27.4% of patients reported PGIC ≥ 5 at 3 months and 48.3% at 6 months. Mild AEs associated with introduction of a second mAb were detected in six patients (15.8%).

CONCLUSIONS

In this real-world study, anti-CGRP mAbs showed safety and effectiveness when administered concomitantly with other mAbs.

Для цитирования: Iannone Luigi Francesco, Romozzi Marina, Russo Antonio, Saporito Gennaro, De Santis Federico, Ornello Raffaele, Sances Grazia, Vaghi Gloria, Tassorelli Cristina, Albanese Maria, Guerzoni Simona, Casalena Alfonsina, Vollono Catello, Calabresi Paolo, Prudenzano Maria Pia, Mampreso Edoardo, Volta Giorgio Dalla, Valente Maria Rosaria, Avino Gianluca, Chiarugi Alberto, Sacco Simona, Pistoia Francesca, Italian Headache Registry (RICe) study group. Association of anti-calcitonin gene-related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study.. European journal of neurology. 2024. DOI: 10.1111/ene.16450.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.